NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke

@article{Bickerdike2009NNZ2566AG,
  title={NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke},
  author={Michael J. Bickerdike and Gregory B. Thomas and David C Batchelor and Ernest S. Sirimanne and Wing Leong and Hai Lin and Frank Sieg and Ji-Yue Wen and Margaret A. Brimble and Paul W. R. Harris and Peter D. Gluckman},
  journal={Journal of the Neurological Sciences},
  year={2009},
  volume={278},
  pages={85-90}
}
View on Elsevier
doi.org
29 Citations
Highly Influential Citations
3
Background Citations
13
Methods Citations
3
Results Citations
3

Figures from this paper

29 Citations

GPE and GPE analogues as promising neuroprotective agents.

This review will focus on structural modifications performed on the GPE molecule in order to obtain bioactive analogues with increased pharmacokinetic profile useful for the treatment of central nervous system injures and neurodegenerative disorders.

The role for IGF-1-derived small neuropeptides as a therapeutic target for neurological disorders

These small neuropeptides provide effective neuroprotection by offering an improved pharmacokinetic profile and more practical route of administration compared with IGF-1 administration.

NNZ-2566, a Glypromate Analog, Attenuates Brain Ischemia-Induced Non-Convulsive Seizures in Rats

Results indicate that NNZ-2566 possesses a unique therapeutic potential as a safe prophylactic agent that synergistically provides neuroprotection and reduces injury-induced seizures.

IGF‐1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions

The research suggests that small neuropeptides have advantages over growth factors in the treatment of brain injury, and that modified neuropePTides designed to overcome the limitations of their endogenous counterparts represent a novel strategy of pharmaceutical discovery for neurological disorders.

Pharmacokinetics and neurotropic effects of cyclo-L-prolylglycine and its modified analogues

CPG shows neuroprotective activity in ischemic-hypoxic and other brain injuries, in addition, it has a complex of other pharmacological effects and therefore CPG can be considered not only as a potential drug, but also as a basic structure for the development of new neurotropic drugs.

Design, Synthesis, and Biological Evaluation of Hybrid Glypromate Analogues Using 2-Azanorbornane as a Prolyl and Pipecolyl Surrogate.

Neurodegenerative disorders of the central nervous system are a class of heterogeneous pathologies affecting millions of people worldwide and represent a global health burden in developed and…

Population pharmacokinetics of NNZ‐2566 in healthy subjects

A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects

This study supports dosing of trofinetide without regard to food, suggesting a negligible food effect and lack of diurnal variation on bioavailability.

Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.

The review covers the evolution of research in this field over the last 25 years and proposes assigning drugs to 19 categories according to their mechanism(s) of action.

A sustainable strategy for the assembly of Glypromate® and its structurally-related analogues by tandem sequential peptide coupling

The protocol ensures stereochemical integrity (determined by VT-NMR and rp-HPLC) and was also successfully applied for the preparation of structurally-related Glypromate® analogues with higher degree of molecular complexity compatible with functionalized amino acids with different side chains.

References

SHOWING 1-10 OF 36 REFERENCES

Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic–ischemic injury

Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic–ischemic adult rats

Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats.

Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat

Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide.

N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats

N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats

The study suggests that peripheral administration of GPE after onset of nigrostriatal dopamine depletion improves long-term Parkinsonian motor deficits, independent of neuronal outcome.

The IGF-I Amino-Terminal Tripeptide Glycine-Proline-Glutamate (GPE) Is Neuroprotective to Striatum in the Quinolinic Acid Lesion Animal Model of Huntington's Disease

It is revealed that exogenous administration of GPE selectively prevents excitotoxin induced phenotypic degeneration of striatal projection neurons and cholinergic and NADPH diaphorase interneurons in an animal model of Huntington's disease.

Endothelin-1 induced middle cerebral artery occlusion: pathological consequences and neuroprotective effects of MK801.

Combining Insulin-Like Growth Factor Derivatives Plus Caffeinol Produces Robust Neuroprotection After Stroke in Rats

The GPE analogue G2MePE by itself had minimal protective effects, but when combined with caffeinol, it demonstrated robust beneficial effects on cortical and subcortical lesion size and behavioral deficit.